Molecular Formula | C19H23O10PS |
Molar Mass | 474.42 |
Storage Condition | Sealed in dry,Room Temperature |
In vitro study | Briciclib has the potential in targeting eIF4E. Briciclib shows inhibitory activity against the proliferation of mantle cell leukemia (EKO-1 and MINO), breast (MCF7 and MDA-MB-231), gastric (AGS), and esophageal (OE19, OE33, and FLO-1) cancer cell lines with GI 50 s of 9.8-12.2 nM, and with no toxicity on normal endothelial cells. Briciclib dose-dependently reduces the expression of cyclin D1 and c-Myc in breast and MCL cancer cell lines within 8 hours. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.108 ml | 10.539 ml | 21.078 ml |
5 mM | 0.422 ml | 2.108 ml | 4.216 ml |
10 mM | 0.211 ml | 1.054 ml | 2.108 ml |
5 mM | 0.042 ml | 0.211 ml | 0.422 ml |